首页|COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer:An allicin-based nanomedicine approach

COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer:An allicin-based nanomedicine approach

扫码查看
原文链接
  • 万方数据
  • 维普
Recently,the utilization of nonsteroidal anti-inflammatory drugs(NSAIDs)to sensitize cisplatin(CDDP)has gained substantial traction in the treatment of ovarian cancer(OC).However,even widely employed NSAIDs such as celecoxib and naproxen carry an elevated risk of cardiovascular events,notably throm-bosis.Furthermore,the diminished sensitivity to CDDP therapy in OC is multifactorial,rendering the ap-plication of NSAIDs only partially effective due to their cyclooxygenase-2(COX-2)inhibiting mechanism.Hence,in this study,reactive oxygen species(ROS)-responsive composite nano-hydrangeas loaded with the Chinese medicine small molecule allicin and platinum(IV)prodrug(DTP@AP NPs)were prepared to achieve comprehensive chemosensitization.On one front,allicin achieved COX-2 blocking therapy,en-compassing the inhibition of proliferation,angiogenesis and endothelial mesenchymal transition(EMT),thereby mitigating the adverse impacts of CDDP chemotherapy.Simultaneously,synergistic chemosensi-tization was achieved from multifaceted mechanisms by decreasing CDDP inactivation,damaging mito-chondria and inhibiting DNA repair.In essence,these findings provided an optimized approach for syner-gizing CDDP with COX-2 inhibitors,offering a promising avenue for enhancing OC treatment outcomes.

COX-2 blocking therapyCDDPChemosensitizationAllicinOvarian cancer

Huijiao Fu、Peiqin Liang、Qianwen Chen、Yan Wang、Guang Li、Xuzi Cai、Shengtao Wang、Kun Chen、Shengying Shi、Zhiqiang Yu、Xuefeng Wang

展开 >

Department of Obstetrics and Gynecology,The Third Affiliated Hospital of Southern Medical University,Guangzhou 510630,China

Department of Obstetrics and Gynecology,Huizhou Central People's Hospital,Huizhou 516001,China

Affiliated Foshan Maternity & Child Healthcare Hospital,Southern Medical University(Foshan Maternity & Child Healthcare Hospital),Foshan 528000,China

Guangdong Key Laboratory of New Drug Screening,School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China

Department of Nursing,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China

Department of Laboratory Medicine,Dongguan Institute of Clinical Cancer Research,The Tenth Affiliated Hospital of Southern Medical University(Dongguan people's hospital),Dongguan 523018,China

展开 >

2024

10.1016/j.cclet.2023.109241

中国化学快报(英文版)
中国化学会

中国化学快报(英文版)

CSTPCD
影响因子：0.771
ISSN：1001-8417
年,卷(期)：2024.35(8)